Sex-based differences in effectiveness of immune checkpoint inhibitors in the treatment of advanced non-small-cell lung cancer: systematic review and meta-analysis
- Published on 05/05/2026
- Reading time: 7 min.
Erick Suazo-Zepeda1, Grietje G Talen1, Sjoukje van der Werf2,3, Jeroen T J N Hiltermann4, Willemijn Maas1, Geertruida H De Bock1, Marjolein A Heuvelmans1,5,6
1Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
2Medical Library, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
3Medical Library, University of Groningen, Groningen, The Netherlands
4Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
5Institute for Diagnostic Accuracy, Groningen, The Netherlands
6Department of Respiratory Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands
Correspondence to Dr Erick Suazo-Zepeda; e.suazo.zepeda@umcg.nl
Abstract
Background Sex-based differences in immune response are well established, but whether men and women derive comparable benefit from immune checkpoint inhibitors (ICIs) in advanced non-small cell lung cancer (NSCLC) remains uncertain. This systematic review and meta-analysis aimed to investigate sex-related differences in effectiveness of ICI for the treatment of advanced NSCLC.
Methods A systematic review and meta-analysis of randomised controlled trials...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
